Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Arachidonic acid metabolites have been shown to modulate the secretion of various hormones, including luteinizing hormone, growth hormone and adrenocorticotropin. In this paper we describe the effect of a series of eicosanoids on hypothalamic secretion of corticotropin-releasing hormone (CRH) in vitro. Explanted rat hypothalami in culture were exposed to prostaglandins (PG) F2 alpha or E2, thromboxane (TX) B2, the TXA2 receptor agonist U-49,619 and leukotrienes (LT) B4, C4 and D4 at concentrations ranging from 10(-15) to 10(-5) M. PGE2, LTD4 and TXB2 did not alter hypothalamic CRH secretion. On the other hand, the remaining eicosanoids tested induced a significant increase of hypothalamic CRH secretion (p less than 0.05). The concentration of 10(-11) M dexamethasone inhibited the effect of stimulatory eicosanoids on CRH secretion. The CRH response to U-49,619 was completely prevented by the TXA2 receptor antagonist SQ-29,548. The latter also inhibited serotonin (5-HT)-, acetylcholine (ACh)- and PGF2 alpha-induced CRH release. Indomethacin was capable of blocking the secretion of CRH induced by 5-HT and ACh. In addition, PGE2 inhibited the increase of CRH secretion induced by PGF2 alpha, 5-HT and ACh. These findings suggest that eicosanoids may be involved in the regulation of hypothalamic CRH secretion, either as autocrine/paracrine or as endocrine factors.
 ...
PMID:Arachidonic acid metabolites modulate rat hypothalamic corticotropin-releasing hormone secretion in vitro. 255 44

The continuous and progressive rise of beta-endorphin (B-EP), beta-lipotropin (B-LPH) and cortisol plasma levels during labor in term-pregnant women represents one of the most relevant maternal hormonal responses to the stress of parturition. The aim of the present study was to evaluate the changes of these hormones, both in plasma and amniotic fluid (except cortisol), in a group of pregnant women undergoing prostaglandin-induced therapeutic abortion at the 2nd trimester of pregnancy. B-EP, B-LPH and cortisol were measured by radioimmunoassay. Both plasma and amniotic fluid samples were purified through extraction and chromatography (Sephadex G-75 columns). The prostaglandin derivative, 16-phenoxy-PGE2-methylsulfonylamide (sulprostone, Schering, Berlin) (500 micrograms, i.m., every 4 h), caused a rapid and significant rise of plasma B-EP, B-LPH and cortisol levels in all subjects. The relative increase of the 3 hormones was less relevant after the 2nd and absent after the 3rd injection of PGE2. The amniotic fluid concentrations of B-EP and B-LPH were also raised 2 h after the 1st injection. These data indicate that sulprostone-induced abortion activates both maternal and fetoplacental release of opioids independently of the trend of uterine contractions. The pattern of pro-opiomelanocortin-related labor differs from spontaneous labor and can probably be linked to a direct effect of the drug.
 ...
PMID:Prostaglandin-induced mid-pregnancy abortion increases plasma and amniotic fluid levels of beta-lipotropin and beta-endorphin. 295 88

The secretion of cortisol from the interrenal tissue in trout Salmo gairdnerii was studied in vivo and by an in vitro superfusion method in relation to the effect of adrenocorticotropic hormone (ACTH), prostaglandins (PGE1, PGF2 alpha) and prostaglandin inhibitors. The experiments were performed between April and July. In control, uninjected animals, circulating cortisol was 206 +/- 24 ng/ml. At 24 h following the intraperitoneal injection of indomethacin, dexamethasone, or both, the levels were reduced to 84 +/- 10, 43 +/- 20 and 63 +/- 11 ng/ml respectively. In control animals receiving solvent (ethanol), the value was 190 +/- 30. With longer term duration (72 h) the levels of plasma cortisol following injection of indomethacin, dexamethasone and both drugs together were 120 +/- 29, 120 +/- 10 and 37 +/- 8 respectively. On the contrary, no significant change was produced by prostaglandins. In vitro release of cortisol from superfused head kidneys (which contain the interrenal tissue of teleosts) decreased gradually with time and reached a minimum after 50 min. Addition of ACTH or of PGE1 to the medium induced an immediate, dose dependent increase in cortisol output which reached a maximum after 15-30 min. On the contrary, PGE2 alpha or indomethacin did not modify cortisol release. These results show that cortisol production in trout, which is controlled by ACTH as in other vertebrates, is also under the influence of other hormonal substances acting on the adenyl-cyclase system.
 ...
PMID:In vivo and in vitro studies on the release of cortisol from interrenal tissue in trout. I. Effects of ACTH and prostaglandins. 298 23

Previous studies in vitro have shown that prostaglandin (PG) E2 is formed in rat adenohypophysis upon stimulation by arginine-vasopressin (AVP) and synthetic ovine corticotropin-releasing factor (CRF-(1-41]. The aim of the present study was to examine whether long-term changes in the hypothalamic stimulation of the pituitary corticotrophs in vivo may influence PG synthesis in subsequent in vitro incubations of rat anterior pituitary quarters. The release of PGE2 from adenohypophyses obtained from adrenalectomized rats was increased to about 300% of controls both under basal conditions and after stimulation by AVP; by contrast, the release of PG D2 was changed neither by adrenalectomy nor by AVP. Simultaneously, basal release of beta-endorphin-like immunoreactivity (beta-EI) was increased after adrenalectomy to about 300% of controls, parallel to the increase in the tissue content, whereas AVP-induced beta-EI release was unchanged. Addition of PG E2 inhibited, whereas blockade of PG formation by indomethacin enhanced AVP-induced beta-EI release both in controls and after adrenalectomy. When anterior pituitary glands were taken from rats with lesions of the paraventricular nuclei, release of PG E2 was decreased as compared to controls both under basal conditions and after stimulation by AVP or CRF-(1-41). Simultaneously, basal and evoked release of beta-EI was unchanged. We conclude that the formation of PG E2 in the adenohypophysis varies according to long-term changes in the hypothalamic stimulation of adrenocorticotropin and beta-endorphin release supporting the view that PG E2 synthesis is related to, and may be involved in mechanisms controlling peptide hormone release from the corticotrophs.
 ...
PMID:Release of prostaglandin E2 and beta-endorphin-like immunoreactivity from rat adenohypophysis in vitro: variations after adrenalectomy or lesions of the paraventricular nuclei. 315 85

The present study was performed to examine the effect of the cyclo-oxygenase inhibitor, indomethacin, and that of various prostaglandins on the release of vasopressin and beta-endorphin-like immunoreactivity (beta-EI) from the rat neurointermediate lobe of the hypophysis, which was superfused in vitro. Indomethacin (2.8 and 28 mumol/l) changed neither basal secretion of vasopressin nor that evoked by electrical stimulation, whereas the resting release of beta-EI was enhanced by indomethacin (28 mumol/l). Prostaglandin (PG) E2 did not influence resting release of vasopressin but markedly inhibited (by about 50%) electrically induced release of vasopressin (least effective concentration: 300 nmol/l) as well as spontaneous secretion of beta-EI (least effective concentration: 100 nmol/l) in the presence of indomethacin (28 mumol/l). Prostaglandin F2 alpha (5 mumol/l) also inhibited the evoked release of vasopressin, whereas PGD2 (5 mumol/l) did not. Prostaglandin F2 alpha (5 mumol/l), D2 and I2 (1.5 mumol/l each) produced no effects on beta-EI release. As observed in the neurohypophysis, PGE2 inhibited the electrically induced release of vasopressin from the medial basal hypothalamus in vitro. We conclude that prostaglandins (especially PGE2) can inhibit (1) the stimulated release of vasopressin when acting on vasopressin-containing nerve terminals of either neurosecretory system (neurohypophysis, median eminence region), and (2) the secretion of beta-EI and, as can be inferred, alpha-MSH, by a direct action on intermediate lobe cells.
 ...
PMID:Inhibition by prostaglandin E2 of the release of vasopressin and beta-endorphin from rat pituitary neurointermediate lobe or medial basal hypothalamus in vitro. 316 Aug 2

The effect of electrical dysrhythmias on the mechanical activity of the fed stomach was investigated in 5 conscious dogs implanted with Ag-AgCl electrodes and strain gauge force transducers. Each dog was fed 1 can of ALPO and electromechanical activities of the stomach were recorded for the next 120 min. The results show that intraarterial boluses of met-enkephalin (75 micrograms/kg), PGE2 (36 micrograms/kg), and epinephrine (36 micrograms/kg) induced episodes of antral dysrhythmias whereas saline (1 cc) did not. The postcibal antral motility index for the test period was not altered following saline injection, but it was reduced by 61%, 70%, and 81% following the administration of met-enkephalin, epinephrine, and PGE2, respectively (p less than 0.01 vs. baseline period). During periods of normal electrical rhythm, PGE2 and epinephrine significantly reduced the antral motility index (2.07 +/- 0.93 and 3.24 +/- 0.79, respectively) vs. saline (7.92 +/- 0.44) (p less than 0.05 for both drugs) whereas met-enkephalin (4.98 +/- 0.56) did not. In contrast, during episodes of dysrhythmia, met-enkephalin significantly depressed antral motility (1.70 +/- 0.74) (p less than 0.05 vs. periods with normal electrical rhythm) whereas neither epinephrine nor PGE2 caused a further reduction in antral motility from what was seen during periods of normal electrical rhythm (1.84 +/- 0.72 and 1.34 +/- 0.37, respectively). We thus conclude that intraarterial administration of met-enkephalin, PGE2, or epinephrine induce gastric dysrhythmias postcibally and depress antral contractile activity. The relaxatory effect of met-enkephalin on antral contractions is primarily due to its dysrhythmic effect whereas PGE2 and epinephrine inhibit antral motility even when the electrical rhythm is undisturbed.
 ...
PMID:Effect of gastric dysrhythmias on postcibal motor activity of the stomach. 342 85

Plasma levels of immunoreactive parathormone (iPTH), immunoreactive calcitonin (iCT) and prostaglandins (PGE2) were measured by RIA in 115 patients with bronchogenic carcinoma. In 37 of these cases the following hormones were also assayed: adrenocorticotropic hormone (ACTH), cortisol, plasma renin activity (PRA), aldosterone, prolactin, human growth hormone (HGH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH) human chorionic gonadotropin (HCG), progesterone (P), androstenedione (A), testosterone (T), estradiol (E2) and dehydroepiandrosterone sulphate (DHAS). High serum levels of many hormone-like substances and hormones were found and the levels of certain hormones varied in some cases according to the clinical evolution of the disease and the response to therapy.
 ...
PMID:Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma. 342 45

The aim of this study was to determine whether food ingestion causes a change in the susceptibility of the stomach to dysrhythmia or in the characteristics of gastric dysrhythmia. The susceptibility of the stomach to develop dysrhythmia was measured by determining the median effective dose of four different drugs known to produce gastric dysrhythmia. These drugs were epinephrine, PGE2, met-enkephalin, and glucagon. The median effective dose for inducing gastric dysrhythmia was measured in four healthy conscious dogs by Dixon's up-and-down method during fasting and after feeding. The median effective dose of epinephrine, PGE2, met-enkephalin, and glucagon were higher after feeding (16.6, 16.6, 35.1, greater than 221 micrograms/kg, respectively) than during fasting (1.7, 5.2, 11.1, 61.0 micrograms/kg, respectively). The results indicate that feeding renders the stomach less susceptible to pharmacologically induced dysrhythmia. However, characteristics of gastric dysrhythmias, such as site of origin and direction of propagation, were similar whether they occurred during fasting or after feeding.
 ...
PMID:Meal reduces sensitivity of the stomach to pharmacologically induced dysrhythmia. 347 88

The consistent occurrence of gastric and duodenal ulcers was observed in laboratory rabbits used for production of high-titer plasma antibody to 6-keto PGF1 alpha and PGE2. Perforations developed in 7 of 10 animals, usually just distal to the pyloroduodenal junction. The remaining rabbits showed gross and/or microscopic evidence of imperforate ulcers and erosions. These lesions appeared to be direct pathologic complications of an immune response directed against prostaglandins since animals immunized against met-enkephalin with similar methods had no ulcers.
 ...
PMID:Gastroduodenal ulceration in rabbits producing antibodies to prostaglandins. 385 14

Prostaglandin E (PGE), epinephrine and metenkephalin are three endogenous substances normally present in the endocrine pancreas which have been reported to inhibit glucose-induced insulin secretion in normal humans. To evaluate possible synergistic interactions between these inhibitory agents upon the regulation of insulin release in man, we examined the effects of PGE, epinephrine and the long-acting met-enkephalin analogue FK 33-824, given alone or in combination, upon glucose-induced insulin secretion in normal man. The infusion of the three agents at doses known to affect insulin secretion (10 micrograms/min, 15 ng/kg/min, 0.5 mg im, respectively) produced the expected inhibitory effects upon insulin responses to an intravenous glucose challenge. The infusion of the three agents at doses which did not produce per se any significant change of insulin responses to glucose (5 micrograms/min, 5 ng/kg/min, 0.2 mg i.m., respectively), caused a significant inhibition of this response when given in combination. In particular, the acute insulin response to glucose decreased from a control value of 50 +/- 9 microU/ml to a value of 21 +/- 6 microU/ml (p less than 0.02). The inhibitory effect of epinephrine (15 ng/kg/min) upon glucose-induced insulin secretion was partially reversed by sodium salicylate, an inhibitor of endogenous prostaglandin synthesis, which increased but not normalized, either the acute insulin response and the glucose disappearance rates. Similarly, the negative effect of FK 33-824 upon glucose-induced insulin secretion was reversed by sodium salicylate. Similar findings were also obtained with indomethacin, another structurally unrelated inhibitor of endogenous prostaglandin synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Interaction between epinephrine, prostaglandin E, and met-enkephalin in the regulation of insulin release in man. 390 78


<< Previous 1 2 3 4 5 6 Next >>